Lupus & antiphospholipid syndrome
Definition and application of systemic lupus erythematosus disease modification in emerging markets: Delphi panel consensus recommendations
Authors' conclusion
There was strong consensus across experts from the Gulf and Latin America that the concept of disease modification can provide a valuable framework to support clinicians for the management of patients with SLE and LN.
Study context
- Population
- Expert Systemic Lupus Erythematosus (SLE) physicians from Argentina, Bahrain, Brazil, Mexico, Oman, Saudi Arabia and United Arab Emirates (Gulf region and Latin America)
- Outcome
- Consensus (>75% agreement) on acceptance and application of the SLE/lupus nephritis (LN) disease modification framework
Methodological detailstwo cross-sectional Delphi surveys, workshop discussion between surveys, consensus >75% agreement, regional analysis (Gulf vs Latin America)
- Two cross-sectional Delphi surveys
- Workshop discussion between surveys
- Consensus >75% agreement
- Regional analysis (Gulf vs Latin America)
Recommendations
As reported in the abstract
Expert consensus on SLE/LN disease modification
- Disease modification definition aspects assessed 'routinely' in current practice
- 31%
- Disease modification definition aspects assessed 'sometimes' in current practice
- 62%
- Biomarkers are a key component of evaluating disease modification
- 91%
- Currently available biomarkers are sub-optimal
- 96%
- Immunosuppressants are disease modifying
- 96%
- Biologics are disease modifying
- 92%
- HCQ is disease modifying
- 88%
Original publication
Definition and application of systemic lupus erythematosus disease modification in emerging markets: Delphi panel consensus recommendations. Lupus. Published 6 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →